Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The predictive value of p53 and p33 ING1b in patients with Dukes'C colorectal cancer

The predictive value of p53 and p33 ING1b in patients with Dukes'C colorectal cancer Objective Identification of biological markers that may predict response to chemotherapy would allow the individualization of treatment by enabling selection of patients most likely to benefit from chemotherapy. The aims of this study were to determine whether p53 mutation status and p53 and p33ING1b protein expression can predict which patients with Dukes’ C colorectal cancer following curative surgical resection respond to adjuvant chemotherapy with 5‐fluorouracil (5‐FU). Method Patients with Dukes'C colorectal cancer (n = 41) were studied. DNA was extracted and analysed for p53 mutation using PCR‐based direct DNA sequencing. Tumours were analysed for p53 protein expression by immunohistochemistry using DO‐7 monoclonal antibody and for p33ING1b protein expression using GN1 monoclonal antibody. Results There was a significant association between p53 mutation status analysed by gene sequencing and overall and metastasis‐free survival (P = 0.03 and 0.004, respectively, log‐rank test). By contrast, no significant correlation was found between p53 and p33ING1b protein expression and overall or metastasis‐free survival. Conclusion In patients with Dukes'C colorectal cancer who underwent curative surgical resection of the primary tumour, followed by 5‐FU‐based adjuvant chemotherapy, p53 mutation status as assessed by gene sequencing is a significant predictor of overall and metastasis‐free survival. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Colorectal Disease Wiley

The predictive value of p53 and p33 ING1b in patients with Dukes'C colorectal cancer

Download PDF
8 pages

Loading next page...
 
/lp/wiley/the-predictive-value-of-p53-and-p33-ing1b-in-patients-with-dukes-c-IXbFXPAPyP

References (38)

Publisher
Wiley
Copyright
© 2007 The Association of Coloproctology of Great Britain and Ireland
ISSN
1462-8910
eISSN
1463-1318
DOI
10.1111/j.1463-1318.2007.01317.x
pmid
17949449
Publisher site
See Article on Publisher Site

Abstract

Objective Identification of biological markers that may predict response to chemotherapy would allow the individualization of treatment by enabling selection of patients most likely to benefit from chemotherapy. The aims of this study were to determine whether p53 mutation status and p53 and p33ING1b protein expression can predict which patients with Dukes’ C colorectal cancer following curative surgical resection respond to adjuvant chemotherapy with 5‐fluorouracil (5‐FU). Method Patients with Dukes'C colorectal cancer (n = 41) were studied. DNA was extracted and analysed for p53 mutation using PCR‐based direct DNA sequencing. Tumours were analysed for p53 protein expression by immunohistochemistry using DO‐7 monoclonal antibody and for p33ING1b protein expression using GN1 monoclonal antibody. Results There was a significant association between p53 mutation status analysed by gene sequencing and overall and metastasis‐free survival (P = 0.03 and 0.004, respectively, log‐rank test). By contrast, no significant correlation was found between p53 and p33ING1b protein expression and overall or metastasis‐free survival. Conclusion In patients with Dukes'C colorectal cancer who underwent curative surgical resection of the primary tumour, followed by 5‐FU‐based adjuvant chemotherapy, p53 mutation status as assessed by gene sequencing is a significant predictor of overall and metastasis‐free survival.

Journal

Colorectal Disease – Wiley

Published: May 1, 2008

There are no references for this article.